Speaking To AstraZeneca And Huma About Digital’s Value For Pharma
Executive Summary
AstraZeneca has been working with Huma to develop a series of software-based tools for monitoring patients. Medtech Insight spoke to both companies about the value of these partnerships and the potential challenges.
You may also be interested in...
Digital Health Roundup: Voice Biomarkers; SXSW, LSI, ACC; FTC BetterHelp Settlement
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb discusses conference highlights from SXSW and LSI while Barnaby Pickering talks about his coverage on voice biomarkers. Hannah Daniel discusses BetterHelp’s return of $7.8m to customers to settle with FTC for sharing health data.
Huma Secures EU MDR Approval For Medtech Software That Can Be Used In Any Disease
Huma Therapeutics has secured the first ever EU regulatory approval for a “disease agnostic” class IIb medtech software platform. CEO Dan Vahdat tells Medtech Insight how the product can be configured to monitor patients with any condition.
Minute Insight: Huma Buys AstraZeneca’s Amaze Digital Health Platform For Chronic Disease
The companies will continue to collaborate to expand the reach of AstraZeneca's Amaze platform for chronic disease while launching companion applications.